Back to Authors

Rothenmund, Heidi

Mayo Clinic

University of Manitoba

Citations 2

A220 SCREENING AND MANAGEMENT OF LYNCH SYNDROME IN CLINICAL PRACTICE
Jain, Avni , Shafer, Leigh Anne , Kim, C, Rothenmund, Heidi, Samadder, Jewel, Singh, Harminder , Gupta, Samir

Journal of the Canadian Association of Gastroenterology | March 15, 2019 | Volume: 2 | Issue: Supplement_2 | Pages: 430-431

10.1093/jcag/gwz006.219 Get It

The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer
Johnson, Michele R., Rabe, Kari G. , Brune, Kieran, Rothenmund, Heidi, Gallinger, Steven , Petersen, Gloria M. , Hruban, Ralph H. , Couch, Fergus J. , Andrade, Mariza de , Goggins, Michael , Klein, Alison P. , Chaffee, Kari G.

Cancer Epidemiology, Biomarkers & Prevention | February 14, 2007 | Volume: 16 | Issue: 2 | Pages: 342-346

10.1158/1055-9965.epi-06-0783 Get It

AbstractMutations in the BRCA2 gene have been implicated in pancreatic cancer susceptibility through studies of high-risk breast and ovarian cancer families. To determine the contribution of mutations in BRCA2 to familial pancreatic cancer, we screened affected probands from 151 high-risk families identified through pancreatic cancer clinics for germ-line BRCA2 mutations. Of these families, 118 had two or more first- and second-degree relatives with pancreatic cancer, and an additional 33 had two or more affected second-degree relatives. The average age of onset for pancreatic cancer was 62.8 years. Five BRCA2 truncating mutations were identified, three in families with two or more first- and second-degree relatives with pancreatic cancer. Three of the families with mutations had a history of breast cancer but not ovarian cancer. Four of five families with mutations were identified through probands with early-onset (<55 years) pancreatic cancer. The results of this study were combined with those from a BRCA2 mutation study of 29 other families from the same Johns Hopkins University National Familial Pancreatic Tumor Registry to estimate the frequency of BRCA2 mutations. A total of 10 carriers from 180 families were identified, suggesting that BRCA2 mutations account for 6% of moderate and high-risk pancreatic cancer families. (Cancer Epidemiol Biomarkers Prev 2007;16(2):342–6)